Healthcare
Tuesday, August 30, 2016
BRIEF-Ribomic says substance patent assessment for anti-midkine aptamers in US
* Says co receives substance patent assessment for
anti-midkine aptamers, which is jointly developed with Otsuka
Pharmaceutical Co., Ltd., in US
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment